Drug Pricing
Our work in Drug Pricing
-
Reining in Pharmaceutical Costs
The administration and lawmakers should prioritize four actions that could engender more cooperation and improve health over the long term.
Categorized in -
PCSK9 Inhibitors Show Value for Patients and the US Health Care System
Schaeffer Center researchers estimate the long-term health and economic value of PCSK9 inhibitors for Americans (51 years and older).
Categorized in -
Follow the Money to Understand How Drug Profits Flow
Only by following the money will a clear understanding emerge of the economic forces roiling the industry and driving price increases.
Categorized in -
Pharmaceutical Industry Profits and Research and Development
Paul Ginsburg and Richard Frank question the premise that more innovation is always a good thing.Â
Categorized in -
Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors
Daniel Blumenthal, Dana Goldman, and Anupam Jena discuss potential for outcomes based pricing strategies.
Categorized in -
Switch and Save on Medicare Part D
Simply switching prescription drug plans could save seniors and the government billions.
Categorized in -
A Billion Here, a Billion There: Selectively Disclosing Actual Generic Drug Prices Would Save Real Money
Opportunities exist to lower spending on generic drugs—and reduce total health care spending.
Categorized in -
Innovative Drugs Deserve Innovative Pricing
For the first time, CMS agreed to a payment plan which is dependent on whether the drug actually produces a benefit to the patient. Novartis will get paid $475,000 only if patients respond to the drug by the end of the first month of therapy.
Categorized in -
To Save on Prescriptions, Buy at Independent Pharmacies and use Coupons
A survey of LA County pharmacies found cash prices for prescriptions can vary widely.
Categorized in -
Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework
This study measured the relationship between randomized controlled trial (RCT) efficacy and real-world effectiveness for oncology treatments as well as how this relationship varies depending on an RCT’s use of surrogate versus overall survival endpoints.
Categorized in